What 5 Analyst Ratings Have To Say About Harmony Biosciences
Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings within the last quarter:
Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61
Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.
Mizuho Maintains Buy on Harmony Biosciences, Lowers Price Target to $60
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and lowers the price target from $64 to $60.
Jefferies Downgrades Harmony Biosciences to Hold, Announces $57 Price Target
Jefferies analyst Chris Howerton downgrades Harmony Biosciences (NASDAQ:HRMY) from Buy to Hold and announces $57 price target.
Raymond James Maintains Outperform on Harmony Biosciences, Raises Price Target to $60
Raymond James analyst Danielle Brill maintains Harmony Biosciences (NASDAQ:HRMY) with a Outperform and raises the price target from $58 to $60.
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Goldman Sachs Downgrades Harmony Biosciences to Neutral, Announces $55 Price Target
Goldman Sachs analyst Corinne Jenkins downgrades Harmony Biosciences (NASDAQ:HRMY) from Buy to Neutral and announces $55 price target.
Mizuho Initiates Coverage On Harmony Biosciences with Buy Rating, Announces Price Target of $64
Mizuho analyst Graig Suvannavejh initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Target of $64.